Total raised
—
Last: Seed 2024-03
Stage
Acquired
Founded
2023
Headcount
2
HQ
Rehovot
Sector
Health Tech & Life Sciences
About
CombinAble offers a revolutionary approach to therapeutic design. Its unique AI platform moves beyond standard antibodies, enabling the rapid in silico development of complex formats, including bi-specifics, tri-specifics, and T-cell engagers.
The platform enables development of best-in-class therapeutics in just 4 months—dramatically faster than traditional methods. This accelerated timeline, even for the most complex biologics, gives our partners a significant competitive advantage.
Funding history · 1 round · — total
2024-03
Seed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Tags
drug-developmentartificial-intelligencebiopharmaceuticalbiotechnologytherapeuticspharmaceuticalsantibodies